The effect of APOE ε4 allele on cholinesterase inhibitors in patients with alzheimer disease: Evaluation of the feasibility of resting state functional connectivity magnetic resonance imaging

Alzheimer Disease and Associated Disorders

Volumn 28, Issue 2, 2014, Pages 122-127

  Wang, Liang ^a   Day, Jonathan ^d   Roe, Catherine M ^a,b   Brier, Matthew R ^a   Thomas, Jewell B ^a   Benzinger, Tammie L ^a,b   Morris, John C ^a,b,c   Ances, Beau M ^a,b,c  

^a Department of Neurology ^*  (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d ST LOUIS COLLEGE OF PHARMACY   (United States)

Author keywords

Alzheimer disease (AD); Apolipoprotein E (APOE); Cholinesterase inhibitor; Functional magnetic resonance imaging (fMRI); Resting state functional connectivity

Indexed keywords

APOLIPOPROTEIN E4; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE; CARBAMIC ACID DERIVATIVE; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONNECTOME; CONTROLLED STUDY; DEFAULT MODE NETWORK; DISEASE SEVERITY; DORSAL ATTENTION NETWORK; DRUG EFFECT; FEMALE; GENE INTERACTION; GENOTYPE; HETEROZYGOTE; HUMAN; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PHARMACOGENETICS; PRIORITY JOURNAL; RESTING STATE NETWORK; RETROSPECTIVE STUDY; SENSORIMOTOR FUNCTION; TREATMENT RESPONSE; BRAIN; DRUG EFFECTS; FEASIBILITY STUDY; FUNCTIONAL NEUROIMAGING; GENETICS; NERVE TRACT; PATHOPHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; BRAIN; CHOLINESTERASE INHIBITORS; FEASIBILITY STUDIES; FEMALE; FUNCTIONAL NEUROIMAGING; GALANTAMINE; HUMANS; INDANS; MAGNETIC RESONANCE IMAGING; MALE; NEURAL PATHWAYS; PHENYLCARBAMATES; PIPERIDINES;

EID: 84901394338     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e318299d096     Document Type: Article

References (40)

1. Whitehouse PJ, Price DL, Struble RG, et al. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science. Mar 5, 1982;215:1237-1239. (Pubitemid 12106486)
2. Bowen DM, Smith CB, White P, et al. Neurotransmitterrelated enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain. 1976;99:459-496.
3. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976;2:1403. (Pubitemid 8004505)
4. Perry EK, Blessed G, Tomlinson BE, et al. Neurochemical activities in human temporal lobe related to aging and Alzheimer-type changes. Neurobiol Aging. 1981;2:251-256. (Pubitemid 12152570)
5. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1154-1166. (Pubitemid 32405709)
6. Poirier J, Delisle MC, Quirion R, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA. 1995;92:12260-12264. (Pubitemid 26014050)
7. Farlow MR, Lahiri DK, Poirier J, et al. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Neurology. 1998;50:669-677.
8. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352:2379-2388. (Pubitemid 40958434)
9. Patterson CE, Todd SA, Passmore AP. Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease. Pharmacogenomics J. 2011;11: 444-450.
10. Bizzarro A, Marra C, Acciarri A, et al. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease. Dement Geriatr Cogn Disord. 2005;20: 254-261. (Pubitemid 41291577)
11. Choi SH, Kim SY, Na HR, et al. Effect of ApoE genotype on response to donepezil in patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2008;25:445-450. (Pubitemid 351630078)
12. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001;57:489-495. (Pubitemid 32757598)
13. Aerssens J, Raeymaekers P, Lilienfeld S, et al. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease. Dement Geriatr Cogn Disord. 2001;12:69-77. (Pubitemid 32149710)
14. Rigaud AS, Traykov L, Latour F, et al. Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease. Pharmacogenetics. 2002;12:415-420. (Pubitemid 34816421)
15. Biswal B, Yetkin FZ, Haughton VM, et al. Functional connectivity in the motor cortex of resting human brain using echo-planar MRI. Magn Reson Med. 1995;34:537-541.
16. Smith SM, Fox PT, Miller KL, et al. Correspondence of the brain's functional architecture during activation and rest. Proc Natl Acad Sci USA. 2009;106:13040-13045.
17. Greicius M. Resting-state functional connectivity in neuropsychiatric disorders. Curr Opin Neurol. 2008;21:424-430.
18. Broyd SJ, Demanuele C, Debener S, et al. Default-mode brain dysfunction in mental disorders: A systematic review. Neurosci Biobehav Rev. 2009;33:279-296.
19. Brier MR, Thomas JB, Snyder AZ, et al. Loss of intranetwork and internetwork resting state functional connections with Alzheimer's disease progression. J Neurosci. 2012;32:8890-8899.
20. Goveas JS, Xie C, Ward BD, et al. Recovery of hippocampal network connectivity correlates with cognitive improvement in mild Alzheimer's disease patients treated with donepezil assessed by resting-state fMRI. J Magn Reson Imaging. 2011; 34:764-773.
21. Li W, Antuono PG, Xie C, et al. Changes in regional cerebral blood flow and functional connectivity in the cholinergic pathway associated with cognitive performance in subjects with mild Alzheimer's disease after 12-week donepezil treatment. NeuroImage. 2012;60:1083-1091.
22. Berg L, McKeel DW Jr, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol. 1998;55: 326-335. (Pubitemid 28146197)
23. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412-2414. (Pubitemid 23346995)
24. Berg L, Miller JP, Baty J, et al. Mild senile dementia of the Alzheimer type. 4. Evaluation of intervention. Ann Neurol. 1992;31:242-249.
25. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
26. Pastor P, Roe CM, Villegas A, et al. Apolipoprotein Eepsilon4 modifies Alzheimer's disease onset in an E280A PS1 kindred. Ann Neurol. 2003;54:163-169. (Pubitemid 36909615)
27. Shulman GL, Pope DL, Astafiev SV, et al. Right hemisphere dominance during spatial selective attention and target detection occurs outside the dorsal frontoparietal network. J Neurosci. 2010;30:3640-3651.
28. Shannon BJ, Raichle ME, Snyder AZ, et al. Premotor functional connectivity predicts impulsivity in juvenile offenders. Proc Natl Acad Sci USA. 2011;108:11241-11245.
29. Hyvarinen A. Fast and robust fixed-point algorithms for independent component analysis. IEEE Trans Neural Network. 1999;10:626-634.
30. Zhang D, Raichle ME. Disease and the brain's dark energy. Nat Rev Neurol. 2010;6:15-28.
31. Jack CR Jr, Petersen RC, Grundman M, et al. Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging. 2008;29:1285-1295. (Pubitemid 351970601)
32. Saykin AJ, Wishart HA, Rabin LA, et al. Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. Brain. 2004;127(pt 7):1574-1583. (Pubitemid 38899410)
33. Petrella JR, Prince SE, Krishnan S, et al. Effects of donepezil on cortical activation in mild cognitive impairment: A pilot double-blind placebo-controlled trial using functional MR imaging. AJNR Am J Neuroradiol. 2009;30:411-416.
34. Bohnen NI, Kaufer DI, Hendrickson R, et al. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2005;76:315-319. (Pubitemid 40299116)
35. Fox MD, Zhang D, Snyder AZ, et al. The global signal and observed anticorrelated resting state brain networks. J Neurophysiol. 2009;101:3270-3283.
36. Van Dijk KR, Hedden T, Venkataraman A, et al. Intrinsic functional connectivity as a tool for human connectomics: theory, properties, and optimization. J Neurophysiol. 2010;103: 297-321.
37. Murphy K, Birn RM, Handwerker DA, et al. The impact of global signal regression on resting state correlations: Are anticorrelated networks introduced? NeuroImage. 2009;44:893-905.
38. Weissenbacher A, Kasess C, Gerstl F, et al. Correlations and anticorrelations in resting-state functional connectivity MRI: A quantitative comparison of preprocessing strategies. Neuro- Image. 2009;47:1408-1416.
39. van Buuren M, Gladwin TE, Zandbelt BB, et al. Cardiorespiratory effects on default-mode network activity as measured with fMRI. Hum Brain Mapp. 2009;30:3031-3042.
40. Chang C, Glover GH. Effects of model-based physiological noise correction on default mode network anti-correlations and correlations. NeuroImage. 2009;47:1448-1459.